Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is growing increasingly genericized in the United States, along with improved patient access to antiepileptic drugs, approval for atypical antipsychotics in the treatment of BPD, and eased restrictions on the prescribing of off-label atypical antipsychotics and antidepressants. At the same time, the expanding generics presence has given U.S. payers greater leverage to control drug treatment costs in BPD. Understanding the current and expected influence of clinical metrics and value-for-dollar on market access and medical practice are key for developers of new therapies for BPD.
- How do payer policies affect the prescribing of branded oral atypical antipsychotics (e.g., Sunovion’s Latuda, Lundbeck/Otsuka Pharmaceutical’s Rexulti, Allergan’s Vraylar) and antidepressants (e.g., Lundbeck/Takeda Pharmaceutical’s Trintellix, Allergan’s Viibryd) in this genericized market?
- In this mature and highly generic treatment landscape, what actions can marketers of therapies used to treat BPD employ to attain successful market access and thus overall sales?
- What are the preferred pharmacoeconomic models for payers when evaluating new BPD therapies and what type of pharmacoeconomic data do they find most compelling?
- To which of their BPD patients do psychiatrists anticipate prescribing the emerging therapies ALKS-3831 (Alkermes), NRX-101 (NeuroRX), and rapastinel (Allergan)? How do payers expect to reimburse these therapies?
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
Markets covered: United States.
- Survey of 101 psychiatrists in the United States.
- Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Key companies: Alkermes, Allergan, AstraZeneca, Lundbeck, NeuroRX, Otsuka Pharmaceutical, SumitomoDainippon Pharma, Sunovion, Takeda Pharmaceutical, and Valeant Pharmaceuticals.
Key drugs: ALKS-3831, aripiprazole (Abilify, generics), Latuda, lamotrigine (Lamictal, generics), lithium, NRX-101, quetiapine IR/XR (Seroquel IR/XR, generics), rapastinel, Rexulti, Trintellix, Viibryd, and Vraylar.
- Reimbursement and contracting.
- Access and prescribing.
- Special topics.
- Opportunities and challenges for emerging therapies.
- Bipolar Disorder - Access & Reimbursement - Detailed, Expanded Analysis (US)
Author(s): Lisa Cloonan, BA; Shruti Srinivas Desai, MS; Sonali Prusty
Lisa joined Decision Resources Group in 2015 as a business insights analyst for the Central Nervous System and Ophthalmology division. In this role, she analyzes the commercial opportunities for pharmacological therapies across the psychiatry space.
Prior to joining Decision Resources Group, Lisa spent 6 years in clinical stroke research at Massachusetts General Hospital. While in the clinical research field, Lisa developed an expertise in neuroimaging analysis, as well as authored and co-authored articles on the influence of white matter hyperintensity burden on stroke risk and recovery. Lisa holds bachelor of arts from Connecticut College, where her course work focused on behavioral neuroscience.
Shruti Desai,.Msc works with the Market Access Insights Solutions team as a Manager. She tracks and analyzes the PBM industry and formulary decisions (exclusions and strategies) implemented by key insurers and PBMs. She also analyses value-based contracts and national trends in the U.S. health insurance industry. Shruti joined DRG in 2015, and authors some of the company’s Health Plan Analysis suite of reports (Medicaid profiles, Exchange profiles, Health Plan profiles) and has also contributed to a neurology-related U.S. Access and Reimbursement report.
Sonali Prusty is a Manager in the U.S Market Access Insights team at Decision Resources Group. She tracks and analyzes various key markets in the U.S. health insurance industry. She joined DRG in 2016 and authors the company’s state-level Medicaid, Exchange, health plan and PBM profiles, which are part of the MCOA, Health Plan Analysis and PBE suites. In addition, she has expertise in value-based contracts and proficiency in generating insights from DRG’s data for U.S. Access & Reimbursement reports. Sonali also has a strong biopharma domain knowledge with an expertise in pipeline analysis, drug and company profiling. She is a therapy area expert with a focus on oncology and inflammation.
Prior to joining DRG, Sonali has a diverse 12 years of experience in pharma/clinical/healthcare industry working with some of the top firms including Deloitte Consulting, Thomson Reuters and Accenture. She has managed multiple projects for Top 20 Pharma companies and has expertise in managing clinical and deal intelligence products. Sonali received her B.Sc. degree in Microbiology from Nagpur University and her M.Sc. degree in Biotechnology from Bangalore University.